newsfilter
← Latest News
GlobeNewswire·

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

RANI
  • Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) announced the immediate appointment of Nicholas Maestas as Chief Financial Officer.
  • Maestas succeeds Svai Sanford, who departed in May 2026 to pursue another professional opportunity.
  • Maestas brings over 10 years of financial leadership experience at clinical-stage biotechnology companies, including roles at Tempest Therapeutics, Alector, and Immune Design.
  • At Tempest Therapeutics, he served as CFO & head of corporate strategy, leading multiple financing transactions such as registered direct offerings, PIPEs, and strategic mergers.
  • Previously at Alector, he oversaw financial planning for a $2.2 billion global collaboration with GSK.
  • Earlier in his career at Immune Design, he contributed to the company's $300 million acquisition by Merck.
  • Maestas holds an MBA in finance & health care management from the Wharton School at the University of Pennsylvania and a bachelor's degree in molecular & cell biology from UC Berkeley.
  • CEO Talat Imran stated that Maestas' experience in biopharma capital markets & corporate strategy makes him well-suited to lead Rani through its next chapter.
  • Maestas expressed commitment to working with leadership to unlock the potential of the RaniPill® platform for oral delivery of biologics.
  • Rani Therapeutics is a clinical-stage company focused on advancing the RaniPill® capsule technology to replace subcutaneous injections or intravenous infusions with oral dosing.
  • The company has successfully conducted preclinical & clinical studies to evaluate the safety, tolerability, & bioavailability of its platform.